Literature DB >> 17729423

Alcohol binging causes peliosis hepatis during azathioprine therapy in Crohn's disease.

Christoph Elsing1, Joerg Placke, Thomas Herrmann.   

Abstract

Patients with inflammatory bowel disease have normal life expectancy and, due to modern immunosuppressive therapies, also a normal quality of life. Since mostly young people are affected, their social behaviour suits this environment. Alcohol binging is an increasingly disturbing factor among young people. We describe a patient with Crohn's disease, treated with azathioprine, who developed peliosis hepatis after three epsiodes of alcohol binging. Liver toxicity was not observed previously during the course of the treatment. Azathioprine-induced peliosis hepatis is thought to be idiosyncratic in humans. From animal studies, however, it is clear that hepatic depletion of glutathione leads to azathioprine toxicity to the sinusoidal endothelial cells. Damage of these cells causes peliosis hepatis. Since alcohol binging leads to hepatic glutathione depletion, we conclude that in our patient the episodes of binging have reduced liver gluathione content and therefore this has increased azathioprine toxicity causing peliosis hepatis. The problem of alcohol binging has not yet been addressed in IBD patients undertaking immunosuppressive therapy. This should be reviewed in future considerations regarding patients advice.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17729423      PMCID: PMC4611844          DOI: 10.3748/wjg.v13.i34.4646

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  14 in total

1.  Ethanol binging exacerbates sinusoidal endothelial and parenchymal injury elicited by acetaminophen.

Authors:  Robert S McCuskey; Nancy W Bethea; Jennifer Wong; Margaret K McCuskey; Edward R Abril; Xiangdong Wang; Yoshiya Ito; Laurie D DeLeve
Journal:  J Hepatol       Date:  2005-03       Impact factor: 25.083

2.  Azathioprine myelotoxicity related to elevated 6-thioguanine nucleotides in heart transplantation.

Authors:  E Schütz; J Gummert; F W Mohr; V W Armstrong; M Oellerich
Journal:  Transplant Proc       Date:  1995-02       Impact factor: 1.066

3.  Veno-occlusive disease, nodular regenerative hyperplasia and hepatocellular carcinoma after azathioprine treatment in a patient with ulcerative colitis.

Authors:  S Russmann; A Zimmermann; S Krähenbühl; B Kern; J Reichen
Journal:  Eur J Gastroenterol Hepatol       Date:  2001-03       Impact factor: 2.566

4.  Incidence, risk factors and clinical course of thiopurine-induced liver injury in patients with inflammatory bowel disease.

Authors:  G Bastida; P Nos; M Aguas; B Beltrán; A Rubín; F Dasí; J Ponce
Journal:  Aliment Pharmacol Ther       Date:  2005-11-01       Impact factor: 8.171

Review 5.  Review article: psychosocial factors in the quality of life of patients with inflammatory bowel disease.

Authors:  A Sainsbury; R V Heatley
Journal:  Aliment Pharmacol Ther       Date:  2005-03-01       Impact factor: 8.171

6.  Survival and cause-specific mortality in ulcerative colitis: follow-up of a population-based cohort in Copenhagen County.

Authors:  Karen Vanessa Winther; Tine Jess; Ebbe Langholz; Pia Munkholm; Vibeke Binder
Journal:  Gastroenterology       Date:  2003-12       Impact factor: 22.682

Review 7.  Cholestatic hepatocellular injury with azathioprine: a case report and review of the mechanisms of hepatotoxicity.

Authors:  J Romagnuolo; D C Sadowski; E Lalor; L Jewell; A B Thomson
Journal:  Can J Gastroenterol       Date:  1998-10       Impact factor: 3.522

8.  Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis.

Authors:  D C Pearson; G R May; G H Fick; L R Sutherland
Journal:  Ann Intern Med       Date:  1995-07-15       Impact factor: 25.391

9.  Toxicity of azathioprine and monocrotaline in murine sinusoidal endothelial cells and hepatocytes: the role of glutathione and relevance to hepatic venoocclusive disease.

Authors:  L D DeLeve; X Wang; J F Kuhlenkamp; N Kaplowitz
Journal:  Hepatology       Date:  1996-03       Impact factor: 17.425

10.  Binge drinking among US adults.

Authors:  Timothy S Naimi; Robert D Brewer; Ali Mokdad; Clark Denny; Mary K Serdula; James S Marks
Journal:  JAMA       Date:  2003-01-01       Impact factor: 56.272

View more
  7 in total

1.  Peliosis hepatis complicated by portal hypertension following renal transplantation.

Authors:  Chia-Ying Yu; Liang-Che Chang; Li-Wei Chen; Tsung-Shih Lee; Rong-Nan Chien; Ming-Fang Hsieh; Kun-Chun Chiang
Journal:  World J Gastroenterol       Date:  2014-03-07       Impact factor: 5.742

2.  Alcohol Use in Patients With Inflammatory Bowel Disease.

Authors:  Guilherme Piovezani Ramos; Sunanda Kane
Journal:  Gastroenterol Hepatol (N Y)       Date:  2021-05

3.  Pituitary adenoma with peliosis: a report of two cases.

Authors:  Safraz Mohammed; Luis V Syro; Bernd W Scheithauer; Alberto Abad; Humberto Uribe; Fabio Rotondo; Eva Horvath; Michael Cusimano; Kalman Kovacs
Journal:  Endocr Pathol       Date:  2009       Impact factor: 3.943

Review 4.  Peliosis hepatis: Personal experience and literature review.

Authors:  Daniele Crocetti; Andrea Palmieri; Giuseppe Pedullà; Vittorio Pasta; Valerio D'Orazi; Gian Luca Grazi
Journal:  World J Gastroenterol       Date:  2015-12-14       Impact factor: 5.742

Review 5.  Focal peliosis hepatis in a colon cancer patient resembling metastatic liver tumor.

Authors:  Wu-Jun Xiong; Li-Juan Hu; Yi-Cheng Jian; Yi He; Wei Zhou; Xin-Lai Guo; Ya-Xin Zheng
Journal:  World J Gastroenterol       Date:  2012-11-07       Impact factor: 5.742

6.  Peliosis hepatis: 2 case reports of a rare liver disorder and its differential diagnosis.

Authors:  Yi-Ning Dai; Ze-Ze Ren; Wen-Yuan Song; Hai-Jun Huang; Dan-Hong Yang; Ming-Shan Wang; Yi-Cheng Huang; Mei-Juan Chen; Jia-Jie Zhang; Yong-Xi Tong; Hong-Ying Pan
Journal:  Medicine (Baltimore)       Date:  2017-03       Impact factor: 1.889

Review 7.  Revisiting the Role of Thiopurines in Inflammatory Bowel Disease Through Pharmacogenomics and Use of Novel Methods for Therapeutic Drug Monitoring.

Authors:  Sheng Zhang Lim; Eng Wee Chua
Journal:  Front Pharmacol       Date:  2018-10-08       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.